Current breast cancer clinical trials

Home: Educational Supplement: Appendix

Abstracts

The following are abstracts of presentations to the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer. They are designed for the use of panelists and participants in the conference and as a reference document for anyone interested in the conference deliberations. We are grateful to the authors for their participation and for supplying these summaries.

Abstracts for the following presentations do not appear:

Tamoxifen—Sir Richard Peto, F.R.S., M.Sc.

Chemoendocrine Combined Therapy—Richard Gray, M.A., M.Sc.

Role of Dose and Dose Intensity for Chemotherapy—Larry Norton, M.D.

 

Jeffrey Abrams, M.D.
Senior Investigator
National Cancer Institute
National Institutes of Health

Jerry Elliott
Program Management and Analysis Officer
Office of Medical Applications of Research
National Institutes of Health

 

 

 

Top | Main Menu

 

Main Menu
Contents
I.
Overview
II.
Factors Used To Select Adjuvant Therapy
III.
Adjuvant Hormone Therapy
IV.
Adjuvant Chemotherapy
V.
Adjuvant Postmastectomy Radiotherapy
VI.
Influences of Treatment-Related Side Effects and Quality-of-Life Issues on Individual Decision-Making About Adjuvant Therapy
Breast Cancer Update's web site
Search our site
Home · Contact us
Terms of use and general disclaimer